LDA is commonly administered for thrombophilic predispositions such as antiphospholipid antibodies that do not completely meet the Sydney classification criteria for APS, protein S deficiency, factor XII deficiency and increased platelet aggregation. This evidence concerns the gene PROS1 and autoimmune polyendocrinopathy.